Morgan Stanley Adagene Inc. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Adagene Inc. stock. As of the latest transaction made, Morgan Stanley holds 77,238 shares of ADAG stock, worth $152,931. This represents 0.0% of its overall portfolio holdings.

Number of Shares

77,238

Previous 99,074 22.04%

Holding current value

$152,931

Previous $150,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	SELL	$1.39 - $2.09 $30,352 - $45,637	-21,836 Reduced 22.04%	77,238 $150,000
Q1 2025 May 15, 2025	SELL	$1.52 - $2.1 $3,240 - $4,477	-2,132 Reduced 2.11%	99,074 $150,000
Q4 2024 Feb 14, 2025	BUY	$1.88 - $3.15 $9,653 - $16,175	5,135 Added 5.35%	101,206 $201,000
Q3 2024 May 14, 2025	BUY	$2.12 - $3.49 $4,615 - $7,597	2,177 Added 2.32%	96,071 $213,000
Q3 2024 Nov 14, 2024	BUY	$2.12 - $3.49 $4,615 - $7,597	2,177 Added 2.32%	96,071 $213,000
Q2 2024 May 14, 2025	SELL	$2.12 - $3.24 $15,501 - $23,690	-7,312 Reduced 7.22%	93,894 $287,000
Q2 2024 Oct 17, 2024	BUY	$2.12 - $3.24 $17,420 - $26,623	8,217 Added 9.59%	93,894 $287,000
Q2 2024 Aug 14, 2024	BUY	$2.12 - $3.24 $17,420 - $26,623	8,217 Added 9.59%	93,894 $287,000
Q1 2024 Oct 17, 2024	SELL	$1.96 - $4.15 $16,105 - $34,100	-8,217 Reduced 8.75%	85,677 $239,000
Q1 2024 Aug 16, 2024	SELL	$1.96 - $4.15 $119,646 - $253,332	-61,044 Reduced 41.61%	85,677 $239,000
Q1 2024 May 15, 2024	SELL	$1.96 - $4.15 $119,646 - $253,332	-61,044 Reduced 41.61%	85,677 $239,000
Q4 2023 Aug 16, 2024	BUY	$1.31 - $1.93 $69,203 - $101,956	52,827 Added 56.26%	146,721 $283,000
Q4 2023 Feb 13, 2024	BUY	$1.31 - $1.93 $54,370 - $80,102	41,504 Added 39.45%	146,721 $283,000
Q3 2023 Nov 15, 2023	BUY	$1.15 - $1.6 $57,441 - $79,918	49,949 Added 90.38%	105,217 $160,000
Q2 2023 Aug 14, 2023	BUY	$1.17 - $1.76 $53,911 - $81,097	46,078 Added 501.39%	55,268 $81,000
Q1 2023 May 15, 2023	BUY	$1.27 - $1.95 $1,581 - $2,427	1,245 Added 15.67%	9,190 $13,000
Q4 2022 Feb 14, 2023	SELL	$0.9 - $1.46 $1.13 Million - $1.83 Million	-1,255,891 Reduced 99.37%	7,945 $10,000
Q3 2022 Nov 14, 2022	SELL	$1.24 - $2.09 $1.4 Million - $2.37 Million	-1,131,744 Reduced 47.24%	1,263,836 $1.62 Million
Q2 2022 Oct 27, 2022	BUY	$1.99 - $3.85 $2.01 Million - $3.89 Million	1,009,107 Added 72.78%	2,395,580 $4.95 Million
Q2 2022 Aug 15, 2022	BUY	$1.99 - $3.85 $2.01 Million - $3.89 Million	1,009,107 Added 72.78%	2,395,580 $4.95 Million
Q1 2022 Oct 27, 2022	SELL	$3.5 - $8.79 $3.53 Million - $8.87 Million	-1,009,107 Reduced 42.12%	1,386,473 $4.85 Million
Q1 2022 May 13, 2022	BUY	$3.5 - $8.79 $2,779 - $6,979	794 Added 0.06%	1,386,473 $4.85 Million
Q4 2021 Feb 14, 2022	BUY	$7.4 - $14.44 $8,887 - $17,342	1,201 Added 0.09%	1,385,679 $11.2 Million
Q3 2021 Nov 15, 2021	BUY	$12.7 - $20.68 $17.6 Million - $28.6 Million	1,384,478 New	1,384,478 $19.9 Million

Others Institutions Holding ADAG

# of Institutions

Shares Held

9.67M

Call Options Held

Put Options Held

View Full List

About Adagene Inc.

Ticker ADAG
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,423,200
Market Cap $86M
Description
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid ...

More about ADAG

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account